α-Galactosylceramide activates antitumor immunity against liver tumor

Hepatology Research

Volumn 41, Issue 2, 2011, Pages 160-169

  Tatsumi, Tomohide ^a   Takehara, Tetsuo ^a   Miyagi, Takuya ^a   Sugiyama, Tsukasa ^a   Aketa, Hiroshi ^a   Sasakawa, Akira ^a   Kanto, Tatsuya ^a   Hiramatsu, Naoki ^a   Hayashi, Norio ^a,b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KANSAI ROSAI HOSPITAL   (Japan)

Author keywords

galactosylceramide; Cytotoxic T lymphocytes; Dendritic cells; Liver; Natural killer cells

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; B7 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL POPULATION; CHROMIUM 51 RELEASE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IMMUNOCOMPETENT CELL; LIVER CANCER; LIVER PROTECTION; LIVER WEIGHT; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR IMMUNITY;

EID: 79251526202     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00743.x     Document Type: Article

References (31)

1. Kawano T, Cui J, Koezuka Y etal. CD1d-restricted and TCR-mediated activation of Vα14NKT cells by glycosylceramides. Science 1997; 278: 1626-9.
2. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-γ- producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 2002; 3: 867-74.
3. Gonzalez-Aseguinolaza G, de Oliveira C, Tomaska M etal. α-Galactosylceramide-activated Vα 14 natural killer T cells mediate protection against murine malaria. Proc Natl Acad Sci USA 2000; 97: 8461-6.
4. Miyagi T, Takehara T, Tatsumi T etal. CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver. Int J Cancer 2003; 106: 81-9.
5. Giaccone G, Punt CJ, Ando Y etal. A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002; 8: 3702-9.
6. Doherty DG, O'Farrelly C. Innate and adaptive lymphoid cells in human liver. Immunol Rev 2000; 174: 5-20.
7. Mehal WZ, Azzaroli F, Crispe IN. Immunology of the healthy liver: old questions and new insights. Gatsroenterology 2001; 120: 250-60.
8. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-96.
9. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997; 90: 3245-87.
10. Fernandez NC, Lozier A, Flament C etal. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999; 5: 405-11.
11. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002; 195: 327-33.
12. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C. Human dendritic cells activate resting NK cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002; 195: 343-51.
13. Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 2002; 195: 335-41.
14. Miller G, Lahrs S, Dematteo RP. Overexpression of interleukin-12 enables dendritic cells to activate NK cells and confer systemic antitumor immunity. FASEB J 2003; 17: 728-30.
15. Kawano T, Cui J, Koezuka Y etal. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14NKT cells. Proc Natl Acad Sci USA 1998; 95: 5690-3.
16. Kitamura H, Iwakabe K, Yahata T etal. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopoteniating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 1999; 189: 1121-8.
17. Sasakawa A, Tatsumi T, Takehara T etal. Activated liver dendritic cells generates strong acquired immunity in α-galctosylceramide treatment. J Hepatol 2009; 50: 1155-62.
18. Mayordomo JI, Loftus DJ, Sakamoto H etal. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996; 183: 1357-65.
19. Tatsumi T, Huang J, Gooding WE etal. Intratumoral delivery of dendritic cells engineered to secrete both interleukin(IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res 2003; 63: 6378-86.
20. Uemura A, Takehara T, Miyagi T etal. Natural killer cell is a major producer of IFN-γ that is critical for the IL-12-induced anti-tumor effect in mice. Cancer Immunol Immunother 2010; 59: 453-63.
21. Yamaguchi S, Tatsumi T, Takehara T etal. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide pulsed dendritic cell vaccines. Cancer 2007; 110: 1469-77.
22. Ferlazzo G, Munz C. NK cell compartments and their activation by dendritic cells. J Immunol 2004; 172: 1333-9.
23. Takagi S, Miyagawa S, Ichikawa E etal. Dendritic cells, T-cell infiltration, and Grp94 expression in cholangiocellular carcinoma. Hum Pathol 2004; 35: 881-6.
24. Iwamoto M, Shinohara H, Miyamoto A etal. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer 2003; 104: 92-7.
25. Kobayashi M, Fitz L, Ryan M etal. Identification and purification of natural killer cell stimulatory factors (NKSF), a cytokine with multiple biological effects on human lymphocytes. J Exp Med 1989; 170: 827-45.
26. Gately MK, Wolitzky AG, Quinn PM, Chizzonite R. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol 1992; 143: 127-42.
27. Pillarisetty VG, Katz SC, Bleier JI, Shah AB, DeMatteo RP. Natural killer dendritic cells have both antigen presenting and lytic function and in response to CpG produce IFN-γ via autocrine IL-12. J Immunol 2005; 174: 2612-18.
28. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 2003; 198: 267-79.
29. Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 2004; 199: 1607-18.
30. Hermans IF, Silk JD, Gileadi U, Salio M etal. NKT cells enhance CD4+ and CD8+ T cells responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 2003; 171: 5140-7.
31. Nishimura T, Kitamura H, Iwakabe K etal. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Int Immunol 2000; 12: 987-94.